The following was in today's ASCO Post.
**************
PALOMA-2: No Overall Survival Benefit Reported With Palbociclib/Letrozole in Advanced Breast Cancer

"The final overall survival analysis of the phase III PALOMA-2 trial has shown no significant benefit for palbociclib given with letrozole, vs letrozole and placebo, as a first-line treatment in hormone receptor–positive, HER2-negative metastatic breast cancer."

The results were reported at the 2022 ASCO Annual Meeting by Richard Finn, MD, Professor of Medicine at the David Geffen School of Medicine, University of California, Los Angeles."
https://ascopost.com/news/july-2022/no-overall-survival-benefit-reported-with-palbociclibletrozole-in-advanced-breast-cancer/?utm_source=TAP%2DEN%2D072622&utm_medium=email&utm_term=4cf962011c9ee11a42cbb2ed9ce1807f